~~<i id='51950CF92C'><strike id='51950CF92C'><tt id='51950CF92C'><pre id='51950CF92C'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

leisure time

author：leisure time 2025-09-28 23:47:28 - browse：5

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Biden's 'march

focus

Wikipedia

focus

explore

focus

hotspot

AmastcellAdobeEachyear,morethan400millionurinarytractinfectionsoccurinpeoplearoundtheglobe.Andresear

WSS

Listen: Your guide to Wegovy's blockbuster heart study

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

Fetal cell organoids grown from amniotic fluid, study finds

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

Where are patients getting their prescriptions for GLP

Ozempic has benefits for kidney disease as well as diabetes

explore

leisure time

focus

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Maui funeral service workers on devastation of fires: 'I'm in shock'

As demand for Covid shots wanes, Moderna seeks its next success

CDC overhauls leadership of center that led response to Covid

Medicare proposal to cover medical devices draws a mixed reaction

The untold story of TV’s first prescription drug ad

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

For AI in health care standards, federal regulators join with industry group

Activists slam private health insurers over coverage restrictions

$1 billion proposal to grow Boston, Massachusetts biotech

Wikipedia

Medicare drug price negotiation continues, as pharma counteroffers

After John Oliver segment, STAT readers share their opioid

Change Healthcare: What is it, why does its cyberattack matter?

Listen: Your guide to Wegovy's blockbuster heart study

The history of OxyContin, told through Purdue Pharma documents

Stem cell biologist probes earliest stages of human development

focus

explore

focus

hotspot